- Home
- SLN vs BWAY Comparison
SLN vs BWAY Comparison
Compare SLN & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLN
- BWAY
- Stock Information
- Founded
- SLN 1994
- BWAY 2003
- Country
- SLN United Kingdom
- BWAY Israel
- Employees
- SLN N/A
- BWAY N/A
- Industry
- SLN Biotechnology: Pharmaceutical Preparations
- BWAY Medical/Dental Instruments
- Sector
- SLN Health Care
- BWAY Health Care
- Exchange
- SLN Nasdaq
- BWAY Nasdaq
- Market Cap
- SLN 299.4M
- BWAY 280.7M
- IPO Year
- SLN N/A
- BWAY 2019
- Fundamental
- Price
- SLN $4.81
- BWAY $15.56
- Analyst Decision
- SLN Buy
- BWAY Strong Buy
- Analyst Count
- SLN 5
- BWAY 2
- Target Price
- SLN $32.60
- BWAY $18.00
- AVG Volume (30 Days)
- SLN 60.5K
- BWAY 89.6K
- Earning Date
- SLN 08-07-2025
- BWAY 08-13-2025
- Dividend Yield
- SLN N/A
- BWAY N/A
- EPS Growth
- SLN N/A
- BWAY 515.14
- EPS
- SLN N/A
- BWAY 0.11
- Revenue
- SLN $27,169,000.00
- BWAY $46,084,000.00
- Revenue This Year
- SLN N/A
- BWAY $339.49
- Revenue Next Year
- SLN N/A
- BWAY $21.74
- P/E Ratio
- SLN N/A
- BWAY $53.74
- Revenue Growth
- SLN 22.28
- BWAY 26.50
- 52 Week Low
- SLN $1.97
- BWAY $7.06
- 52 Week High
- SLN $20.48
- BWAY $16.00
- Technical
- Relative Strength Index (RSI)
- SLN 34.88
- BWAY 72.89
- Support Level
- SLN $4.91
- BWAY $14.70
- Resistance Level
- SLN $5.34
- BWAY $16.00
- Average True Range (ATR)
- SLN 0.48
- BWAY 0.64
- MACD
- SLN -0.05
- BWAY 0.18
- Stochastic Oscillator
- SLN 0.71
- BWAY 89.52
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
About BWAY BrainsWay Ltd.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.